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Acquiring a patent in today's patent systems requires in-depth
knowledge of the procedure for both product patenting and process
patenting. When developing nations create or adopt new policies,
they seldom take into account proper policies for patenting.
Consequently, their industrial growth is limited by ineffective patent
procedures. Recent treaties that address patent procedures, the
Trade-Related Aspects of Intellectual Property Rights ("TRIPS")
and the Patent Cooperation Treaty, do not properly assist developing
nations in forming adequate patent and claiming procedures.
Developing nations must harmonize structural procedures with
TRIPS and develop effective patent procedures to achieve stronger
industrial growth. India is used as a case study to show how
developing nations have unsuccessfully instituted patent procedures
in contrast to developed nations such as the United States and, to a
lesser extent, the European Union. Until developing nations have
proper patent procedures, their industrial growth will be limited.
These nations should be given the proper tools to effectively patent
new products and thereby stimulate local invention.
I. INTRODUCrION
Patent procedures require sophistication, acquired by a thorough
understanding of the functioning of the patent system, for successful
implementation. The ability of the patent system to provide a wide
range of protection for inventions within the same product classification
is one thing that marks such sophistication. Procedural tools like claims,
specifications, written descriptions, and patent doctrines all contribute
toward building a sophisticated system of patent protection. For
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example, claims induce precision in defining patents. Developed nations
achieve industrial growth by supplementing patent legislation with
complementing procedural requirements, thus facilitating a wider range
of inventions.
Developing nations lack exposure to the role that procedures play,
especially patent procedures, in implementing policies. In the past, the
lack of proper procedures has resulted in the denial of patent protection
for inventions distinguished through functional structural additions or
even process innovations. For example, some innovations within India
currently labeled as "copies" of Western patents, may, in the United
States, be eligible for patents using appropriate patent techniques.'
Unfortunately, international conventions, especially the Trade-Related
Aspects of Intellectual Property Rights ('TRIPS")2 and the Patent
Cooperation Treaty,3 do not supplement policy prescriptions with
procedural requirements Neither treatise edifies developing countries
about the finer distinctions of patenting procedures and claiming
mechanisms. Thus, developing countries will be impeded in the future
from benefiting from patents in spite of embracing the TRIPS patent
policy. Consequently, innovations of developing nations could be left
unprotected, which affects research and distorts the objectives of the
World Trade Organization ("WTO"). Without commenting on the
TRIPS patent policy, this Article argues that even if developing nations
fully comply with TRIPS, structural harmonization divorced from
adequate procedural mechanisms will merely stunt research and
development Until comparable levels of procedural sophistication are
enabled, merely establishing a TRIPS-compliant patent regime will not
equip developing nations with the tools to protect all innovations.
India is used as a case study in this paper to demonstrate the
consequences for developing countries that lack sophisticated patenting
procedures. Without meaning to generalize, India is the choice case
study for two reasons. First, India is a prominent developing-nation
player in many industries, including the information technology and
chemical process industries (such as pharmaceuticals production).
Second, patent regimes of important developing nations, such as Brazil,
1. See discussion infra Section II.A.2 (highlighting how some of the "copycat" drugs will be
eligible for patent protection in the United States).
2. Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, 33
I.L.M. 81 [hereinafter TRIPS).
3. Patent Cooperation Treaty, June 19, 1970, 28 U.S.T. 7645.
4. The term "procedural requirements" will refer to application standards, such as written
description or best mode, and will include, where appropriate, patent doctrines that enable
interpretation of the patent.
5. In analyzing developing nations, this Article addresses two periods. The terms "current
patent regime" or "pre-TRIPS patent regime" refer to the patent regimes in developing nations before
TRIPS-compliant product patent regimes are established. The term "post-TRIPS" refers to the
product patent regime that will be established as required under Article 27 of TRIPS.
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South Africa, and Thailand, bear remarkable similarity to the Indian
patent regime. 6
Section II introduces the two regimes of patenting: product
patenting and process patenting. The process patent regime presumably
allows the duplication of an already patented product. A discussion on
the patent policy contemplated by TRIPS is followed by an analysis of
the procedural tools that will be used in the developed and developing
nations to implement TRIPS.
Section III analyzes how claiming mechanisms in the United States
enable the benefits of a process patent system within a product patent
regime to be realized, as well as the role of claims in facilitating
inventions either through functional or structural additions within the
same product range. The consequences for developing countries that
lack sophisticated patenting procedures are demonstrated by a case study
of India.
Section IV examines biotechnology patents in the United States and
articulates how procedures create the flexibility required within patent
policies to induce industrial development.
In Section V, this Article concludes that until comparable levels of
procedural sophistication are enabled, merely establishing a TRIPS-
compliant patent regime will not equip developing nations with the tools
to protect all innovations.
II. PRODUCr AND PROCESS PATENTS
A. Patent Types
1. Product and Process Patent Regimes
A patent may be granted for either a product or a process. The
United States and Europe embrace the product patent regime that
protects the end product. Traditionally, developed nations' protection
for innovative processes' has been couched in the acclaimed principle
6. See, e.g., Srividhya Ragavan, Can't We All Get Along? The Case for a Workable Patent
Model, 35 ARIZ. ST. L.J. 117, 135-37 (2003) (discussing Indian and Brazilian law on patents); see also
Judy Reh, International Governance Through Trade Agreements: Patent Protection for Essential
Medicines, 21 Nw. J. INT'L L. & Bus. 379, 400-03 (2001) (discussing patent rights for AIDS drugs in
South Africa and Thailand).
7. Developed nations like the United States, for example, traditionally protect innovative
processes of known patented products using process claims. See Thomas Bilodeau, Case Note, When
Are Pharmaceutical Products Materially Changed from an Intermediate Compound? Eli Lilly v.
Cyanamid, 6 GEO. MASON L. REV. 339, 344 (1998) (discussing that if a product is "old" or
unpatentable, the only patent protection available to a company could be a process patent).
Generally, the process inventor would not seek to claim the product, but would only claim the newly
discovered method or process. See generally In re Tarczy-Hornoch, 397 F.2d 856 (C.C.P.A. 1968)
(discussing process claims).
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that a "patent claim addressed towards a process could not be infringed
by activities involving a product made by that or another process."8
Thus, at all times, developed nations protect the product even if it only
embodies a novel process.
The process patent regime of developing nations does not protect
the product; instead the method or the process of making the product is
protected to the exclusion of the product. Hence, identical products can
be produced by several manufacturers who each hold a process patent.
Protecting innovative processes encourages innovation in the methods of
making known products, although the lack of product patent protection
stunts the research and development of new products. Most developing
countries encourage the use of process patents for food, drug, and
pharmaceutical products, as well as chemical processes.9 Developing
countries have used the flexibility afforded by process patents to
innovate cheaper methods of making expensive patented products, such
as pharmaceuticals. They tend to keep inventions in critical subject
matters, like food, drugs, and chemicals, away from product patent
protection in order to increase market competition through process
innovations, cater to public health, and address other social concerns.10
2. TRIPS Regime
TRIPS seeks to enhance patent protection in developing nations
and to prevent distortion in trade arising from the duplication of
patented products. 1 Article 27 of TRIPS stipulates that "patents shall be
available for any inventions, whether products or processes, in all fields
of technology." ,2 TRIPS standardizes the product patent regime by
8. MARTIN J. ADELMAN ET AL., CASES AND MATERIALS ON PATENT LAW 1012 (1st ed. 1998).
9. For example, the Indian Patents Act reads as follows:
In the case of inventions:
(a) claiming substances intended for use, or capable of being used, as food or as medicine or drug,
or
(b) relating to substances prepared or produced by chemical processes (including alloys, optical
glass, semi conductors and inter metallic compounds), no patent shall be granted in respect of
claims for the substance themselves, but claims for the methods or processes of manufacture shall
be patentable.
Patents Act of 1970,27 India A.I.R. Manual 450 § 5 (1979) [hereinafter Indian Patents Act].
10. See Ragavan, supra note 6, at 150-52.
11. TRIPS, supra note 2, at art. 27. The product patent regime in TRIPS does not necessarily
exclude patenting of inventive processes. Article 27 read with Article 28 clarifies that innovative
processes are patentable although there is no mention of excluding the product from protection. Id. at
art. 28(1)(b). Article 28 details that patented processes are infringed by "products obtained directly by
that process," thereby suggesting that products obtained by alternate processes do not infringe the
process patent. Id. Similarly, Article 34 of TRIPS provides that when an identical product is produced
without the consent of the patent owner, for the purposes of determining infringement, judicial
authorities can "order the defendant to prove that the process to obtain an identical product is
different from the patented process." Id. at art. 34(1). TRIPS therefore specifically suggests that
products using a process not claimed in the patent application will be considered non-infringing.
12. Id. at art. 27.
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providing a uniform international norm. 3 TRIPS favors the product
patents since developed nations argue that the exclusion of the product
in the process patent regimes distorts international trade by allowing
duplication of the patented product using different processes.14 The
rhetoric of the developed nations has been that the product patent
regime provides more effective protection and prevents all forms of
duplication. TRIPS, however, does not suggest any particular claiming
mechanism or procedures to provide effective patent protection.
Essentially, TRIPS deprives developing countries of the flexibility to
exclude subject matters like food, drugs, and chemicals from product
protection. Later sections of this Article will demonstrate that claiming
techniques can incorporate flexibilities even within the product patent
regime. In effect, it is not the patent law as such, but the various
doctrines and claiming mechanisms that balance patent owners' rights
with the societal need for the product. The lack of guidance in
international treatises on the procedural techniques and patent doctrines
will be a disadvantage to developing nations in the post-TRIPS period.
B. Patent Procedures
The following section outlines and compares the development of
procedural techniques in India and the United States in order to
demonstrate the impact of claiming techniques on successful
implementation of patent regimes.
1. U.S. Patent Claims
Claim construction is the heart and soul of the U.S. patent system.
Patent applications propose one or more claims which formally state the
subject matter of the invention with specificity. The claim is a precise
description of an invention's elements and their interactions.! U.S.
courts measure the scope of patent protection from a careful reading of
the various claims. The statutory guidance in 35 U.S.C § 112 is
supplemented by the U.S. Patent and Trademark Office guidelines on
13. Id.
14. For example, in 1989 alone, estimates of the United States' "exports of goods and services
embodying intellectual property amounted to nearly $60 billion." Robert Pechman, Seeking
Multilateral Protection for Intellectual Property: The United States "TRIPs" over Special 301, 7 MINN. J.
GLOBAL TRADE 179, 183 (1998).
15. Calvin Fan, Construing Product-by-Process Patent Claims in Scripps and Atlantic, 28 U.C.
DAVIS L. REV. 219,226 (1994).
16. 35 U.S.C. § 112 (2000). The statute elaborates that:
[the] specification shall contain a written description of the invention, and of the manner and
process of making and using it, in such full, clear, concise, and exact terms as to enable any person
skilled in the art to which it pertains, or with which it is most nearly connected, to make and use
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claim drafting and the decisions of the U.S. Court of Appeals for the
Federal Circuit on claim interpretation. 7
Here is a sampling of the types of claims: Product-by-process claims
describe the product by defining the process of production." The patent
will protect the product produced by the patented process. Jepson claims
define an invention by reciting the admitted prior art in the preamble
and by introducing an improvement clause which recites the ambit of the
invention." Claim limitations can be stated either in functional or
structural terms. Functional claims describe the product by its function.0
The patent will vest on the product performing the specified function.
Structural claim limitations are typically used for biotechnology
inventions to describe product structure and limitations." The means-
plus-function claim limitations define the function and the means or
mechanism that enables the product to perform the function.22 The
patent vests in the product if it performs the function using the specified
means described in the claim. Therefore, a product performing the same
function with different means is eligible for another patent.
Claims allow for both the broadening and the narrowing of an
invention's scope. The precision in defining the scope of an invention
leaves room for more innovation. Claims facilitate catering to a wider
range of inventions within the same product classification. The use of
adequate claiming techniques ensures protection for even minor
inventions and provides the incentive for industries working in the same
field to evolve and capitalize on the benefits.
2. Claiming Requirements in India
The Indian patent legislation provides that every patent application
should embody either a provisional or a complete specification.
a. Provisional Specification
A provisional specification, submitted to the patent office when the
inventor has a prototype, describes the nature of the invention and its
intended manner of working.24 Section 10 of the Patents Act, read with
17. See, e.g., Utility Examination Guidelines Issued by the Patent and Trademark Office, 60 Fed.
Reg. 36,263 (July 14, 1995); see also Lisa A. Karczewski, Biotechnological Gene Patent Applications:
The Implications of the USPTO Written Description Requirement Guidelines on the Biotechnology
Industry, 31 MCGEORGE L. REv. 1043, 1064-66 (2000) (detailing the importance of these guidelines).
18. See ADELMAN, supra note 8, at 647. See generally At. Thermoplastics Co. v. Faytex Corp.,
970 F.2d 834 (Fed. Cir. 1992).
19. ADELMAN, supra note 8, at 677.
20. See In re Donaldson Co., 16 F.3d 1189, 1193-96 (Fed. Cir. 1994); 35 U.S.C. § 112(6) (2000)
(discussing the means-plus-function approach, which is unique to the U.S. system).
21. See ADELMAN, supra note 8, at 680.
22. Id.
23. Indian Patents Act, supra note 9, § 7(4).
24. Id. § 10(1).
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Rule 15 of the Patent Rules, states that the title of the provisional
specification should mention the area of science, a description, and
essential features of the invention.2' The provisional specification secures
the benefit of the filing date as the priority date. 6 India embraces a first
to file system, and therefore the date of filing determines the priority.
b. Complete Specification
A complete specification is filed within twelve months of filing the
provisional specification, otherwise the application is deemed
abandoned.2 ' The filing period encourages the inventor to conduct
research and incorporate the results into the application.28 Every
complete specification should:
(a) fully and particularly describe the invention and its
operation or use and the method by which the invention is
to be performed,
(b) disclose the best method of performing the invention which
is known to applicant... , and
(c) end with a claim or claims defining the scope of the
invention for which protection is claimed.
The terms "description of the invention" and "best mode" are not
statutorily defined.30 The only statutory guideline for claim construction
is in Section 10(5) of the Indian Patents Act,31 detailing that claims
should be clear, succinct, and fairly based on the matter disclosed in the
specification.
Lack of adequate statutory definition has left claim and specification
construction within the courts' domain.33  The courts construe
specifications and claims as a matter of law.34 The Delhi High Court has
held that claims should specify particular features of the device, the
distinguishing features from the prior art, and the nature of the
25. Id.; Indian Patent Rules, Rules 10, 14-20 (1972) (elaborating the requirements of drawings
and models for the specifications).
26. Indian Patents Act, supra note 9, § 11(3)(a). The Act states that the patent applicant will get
the advantage of the priority date provided the nature, characteristics of the technology, or invention
remains unchanged. Id. This principle is commonly known as the "Fairly Based Rule."
27. Id. § 9(1) (stating that, upon request, the controller can grant up to fifteen months to file the
complete specification).
28. Id. § 17(1). The Act notes that applicants may request to post-date the application by six
months. Id. However, the priority dates will also be appropriately post-dated. Id. §11(7).
29. Id. § 10(4). The Indian Patent Rules 14-20 (1972) elaborate the requirements for drawings
and models included within the specifications.
30. Indian Patents Act, supra note 9, § 2. After the complete specification is filed, the examiners
determine procedural validity and compliances before prosecuting claims. See id §10.
31. Id. § 10(5).
32. Id.
33. See Lallubhai Chakbhai Jariwalla v. Chinamanlal Chunilal, 1935 I.L.R. 60 (Bom.) 261, 275-
34. See, e.g., id.
No. 11
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invention.35 The applicant should describe the nature36 and the limits of
the claim with clarity.37 The Bombay High Court has previously noted
that the title of the invention claimed has little consequence in
controlling the claim.38 No additional guidelines supplement the above
broad rules of interpretation laid by the courts, and this leaves unfettered
discretion to the patent office and the judiciary to construe patent claims.
Thus, claim construction is very subjective and unlimited in India. The
lack of a structured claiming mechanism results in unclear definitions and
descriptions of the scopes of inventions. Furthermore, it results in the
presumption of very broad patents and limits the scope of further
inventions.
III. PATENT DISADVANTAGES
The following section traces the role of claims in encouraging
innovation by defining the precise scope of patents. Two particular
claiming mechanisms are analyzed to demonstrate how inadequate
procedural techniques can be detrimental to the successful
implementation of patent policies in developing nations.
A. Product-by-Process Claims and Duplication of Products
1. Product-by-Process Claims in the United States
Traditionally, the use of a product-by-process claim enabled the
patenting of a "product produced using the claimed process."3 9 Since the
product-by-process claim merely protects a product produced by the
claimed process, the status of an identical product produced by using a
different process was left undetermined. Recent U.S. decisions have
reiterated that the protection offered by product-by-process claims
allowed the duplication of the product using a different process,
effectively only protecting the process of making the product.
40
In 1991, the Federal Circuit in Scripps Clinic & Research Foundation
v. Genentech, Inc. explained the United States' position at that time
regarding the use of product-by-process claims.4' The patent at issue
described a method for purifying and concentrating Factor VIII:C, the
blood clotting factor, by using a monoclonal antibody.42 Claim 1
35. Ram Narain Kher v. Ambassador Indus., 1976 A.I.R. 63 (Del.) 87, 88.
36. Press Metal Corp. v. Noshir Shorabji Pochk Hanawalla., 1983 A.I.R. 70 (Bom.) 144.
37. See, e.g., Raj Prakash v. Mangath Ram Choudhary, 1978 A.I.R 65 (Del.) 1.
38. See Lallubhai, 1935 I.L.R. 60 (Bom.) 261,290.
39. Mark D. Passler, Product-by-Process Patent Claims: Majority of the Court of Appeals for the
Federal Circuit Forgets Purpose of the Patent Act, 49 U. MIAMI L. REV. 233, 234 (1994).
40. See Atl. Thermoplastics Co. v. Faytex Corp., 970 F.2d 834, 843-46 (Fed. Cir. 1992).
41. 927 F.2d 1565, 1583-84 (Fed. Cir. 1991).
42. Id. at 1568-70.
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contained a process claim providing for "[a]n improved method of
preparing Factor VIII T rocoagulant activity protein" and the process of
preparing the protein. Claim 13 was a product-by-process claim and
provided for "[h]ighly purified and concentrated human or porcine
VIII:C prepared in accordance with the method of claim 
1." 44
Genentech, the accused infringer, produced Factor VIII:C by a process
different from that in the Scripps specification.
The Federal Circuit held that the protection for a product, patented
by the use of the product-by-process claims, is "not limited to products
prepared by the process set forth in the claims., 46 The court noted that
the product-by-process claims allow the inherent characteristics of the• • • 47
product to be claimed using the process limitations. The court
authorized Scripps Clinic to claim purified Factor VIII:C whether
derived through Scripps's disclosed process or any other process
achieving the same result.4 It also noted that both the product and the
process were protected by the use of the product-by-process claims. The
Scripps Clinic decision therefore implied that products protected by the
use of product-by-process claims could not be infringed by using another
process.
Nonetheless, one year later in Atlantic Thermoplastics Co. v. Faytex49 .... 5
Corp. , the Federal Circuit reversed the Scripps Clinic position.0  In
Atlantic, the plaintiff owned a patent comprising of process and product-
by-process claims for a shock-absorbing shoe innersole made from an
elastomeric material and polyurethane foam. "1 The issue involved the
defendant's innersoles with elastomeric heel inserts. 2 Defendant bought
the product from two separate manufacturers using different
manufacturing processes. 3  The plaintiff brought suit against the
defendant for infringing the patent; therefore, the suit related to both of
the manufacturing processes. The Federal Circuit held that the process
of one manufacturer infringed the patent because it contained all the
43. Id. at 1570.
44. Id.
45. Id. at 1569. It used recombinant DNA technology, i.e., isolating the gene encoding the
protein, inserting it into a host cell, replicating the cell, causing the cell to excrete the protein into a
culture medium, and purifying the protein from the medium using Factor VIII:C monoclonal
antibodies. See Donald S. Chisum, Patent Law Developments in the United States Court of Appeals for
the Federal Circuit During 1991, 41 AM. U. L. REV. 869,903 (1992).
46. Scripps Clinic, 927 F.2d at 1583.
47. Id.
48. Id.
49. 970 F.2d 834 (Fed. Cir. 1992), reh'g en banc denied, 974 F.2d 1279 (Fed. Cir. 1992).
50. Id. at 846-47. See also At]. Thermoplastics Co. v. Faytex Corp., 974 F.2d 1279, 1280 (Fed.
Cir. 1992) (Rich, J., dissenting) (commenting harshly on majority's denial of rehearing en banc). See
generally William E. McGowan, Case Comment, Atlantic Thermoplastics Co. v. Faytex Corp., 970
F.2d 834 (Fed. Cir. 1992), 27 SuFFOLK U. L. REV. 300 (1993).
51. Atd. Thermoplastics Co., 970 F.2d at 835.
52. Id.
53. Id. at 836.
54. Id. at 835.
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claim limitations.5 The second manufacturer used a different process to
achieve an indistinguishable product. 6 The Federal Circuit ruled that the
use of a different process (provided it was not a "substantially identical"
process) did not amount to an infringement of the product-by-process
claim. 7 The Federal Circuit overruled Scripps Clinic by holding that a
product claimed by a product-by-process description is only infringed
when the allegedly infringing product is produced using the claimed58
process. In clearer terms, the Atlantic holding meant that product-by-
process claims only protect the product when made by the claimed
method. 9 Accordingly, if a defendant uses a different process to make
the same product, the defendant does not infringe a product patented
using the product-by-process claims. ° Although the court did not
consider the issue of the doctrine of equivalents, the judgment allows
third parties to use different processes to produce a product patented
using the product-by-process claims.6
Case law after Atlantic has opined that it is the controlling law and
has ruled that products produced using different processes do not
infringe a product-by-process claim.62 Authorities on patents, such as
Professor Chisum, have interpreted that product-by-process claims are
not infringed unless the product is made through a substantially identical
63process.
Although the U.S. patent system does not provide for process
protection to the exclusion of the product, the use of appropriate
interpretive strategies on claiming techniques allow, as non-infringing,
55. Id.
56. Id. at 837-38.
57. See id. at 838-47. Interestingly, the court does not define what would amount to a
substantially identical process. Id. The court gave no guidelines to elevate an alternate process of
producing the patented product to a substantially identical process capable of infringing the patented
product. Id.
58. Id. at 838-46.
59. Id. at 846-47.
60. Id.
61. Recent Cases, Trustees of Columbia University v. Roche Diagnostics GmbH, 126 F. Supp.
2d. 16 (D. Mass. 2000), 115 HARV. L. REv. 923, 929 (2002) (arguing that, "[t]aken together, Atlantic
and Scripps define a doctrine of equivalents that applies to the construction of product-by-process
claims.").
62. Tropix Inc. v. Lumigen, Inc., 825 F. Supp. 7, 10 (D. Mass. 1993). But see Trustees of
Columbia Univ. v. Roche Diagnostics GmbH, 126 F. Supp. 2d. 16, 31-32 (D. Mass. 2000) (construing
the scope of the product-by-process claims, the court acknowledged that the law was in a "state of
uncertainty," but concluded that, sitting as a lower court, it lacked authority to select a rule based on
policy considerations). The court rejected the approach of Tropix Inc., which had held that Atlantic
states the controlling law, and instead based its conclusions on the reasoning that an en banc or higher-
court ruling could overrule a panel decision. Id. In the absence of such a ruling, the court found the
first panel opinion in Scripps controlling. Id. See also Recent Cases, supra note 61, at 930 ("The
district court in Columbia based its finding of a conflict between Scripps and Atlantic on an
unnecessarily broad and abstract reading of the cases' holdings, a reading at odds with the policies
underlying product-by-process claims."). See generally, Lawrence A. Hymo & Richard A. Anderson,
Product-by-Process Claims: Time for Reexamination, 3 FED. CIR. B.J. 131 (1993) (arguing that the
decisions can be reconciled based on the history of the claims and the rule of necessity).
63. See 3 DONALD S. CHISUM, CHISUM ON PATENTS § 8.05 [1] (2002).
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the use of different processes of producing patented products. In effect,
thanks to the Atlantic panel, although the product is allegedly protected,
the patent protection is limited to the process of production. 64 Post-
Atlantic, industries in developed nations can capitalize through process
innovations by competitively marketing same or similar products using
different and less expensive processes without infringing the existing
patents. This Article later highlights how the Atlantic panel used U.S.
patent law in a way that patent scholars have vehemently opposed for
patent systems in developing nations.
2. The Purpose-Limited-Product Claims of Europe
Under the European Patent Office Guidelines ("EPO Guidelines"),
"[c]laims for products defined in terms of a process of manufacture are
allowable only if the products as such fulfill the requirements for
patentability."6 ' The EPO Guidelines specify that a "product is not
rendered novel merely by the fact that it is produced by means of a new
process," which implies by exclusion that such a product may be non-
infringing albeit unpatentable. 66 Europe, however, allows the limited
patenting of a known product (even if it is manufactured using a claimed
process), provided a new use of the product is disclosed. Thus, Europe
actually goes one step further than the United States to provide patent
protection for identical products, subject to claiming a new use.
In Europe such patents are titled "use innovations" and can be
protected using "purpose-limited-product claims. 6 7 These claims limit
the scope of patent protection to the particular purpose or use of the
product. Generally, the purpose-limited-product claims are used only
when the product is already patented. For example, a patent application
made in 1979 for pyrrolidine derivatives in the European Patent Office
("EPO") contained active therapeutic substances to reduce cerebral
insufficiencyi5 The Examining Division of the EPO reasoned that public
knowledge of pyrrolidine derivatives destroyed novelty even though the
pharmaceutical use of the derivatives was unknown.6  On appeal, the
64. See generally Atd. Thermoplastics Co. v. Faytex Corp., 970 F.2d 834 (Fed. Cir. 1992), reh'g en
banc denied, 974 F.2d 1279 (Fed. Cir. 1992).
65. See EUROPEAN PATENT OFFICE, GUIDELINES OF EXAMINATION IN THE EUROPEAN PATENT
OFFICE, pt. C, ch. III, para. 4.7b, at http://www.european-patent-office.org/legal/
gui-lines/pdf_2003/gui_03-full-e.pdf (last visited Apr. 15, 2004) [hereinafter EPO GUIDELINES].
66. Id. But see ADELMAN, supra note 8, at 661 (discussing the EPO Guidelines, which state that
"European patent law recognizes 'product-by-process' claims to reach the product as obtained by any
possible process").
67. See How to Claim Medical Methods in the European Patent Office, at http://www.jenkins-
ip.com/serv/serv_7.htm (last visited Apr. 7, 2004).
68. See Hoffman-La-Roche/Pyrrolidine Derivatives, Case T128/82, [1984] E.P.O.R. 591, 592
(EPO Technical Bd. App.); see also EPO Patent No. 79 100 378.3 (issued Feb. 9, 1979); U.S. Patent
No. 4,239,770 (issued Dec. 16, 1980). The derivative belonged to a general formula containing o-
methoxybenzoyl, m-methoxybenzyl, p-methoxybenzyl, or p-fluorbenzyl. Id.
69. See Hoffnan-La-Roche/Pyrrolidine Derivatives, [1984] E.P.O.R. at 593 (refusing the
application on the grounds that it failed to fulfill the requirements of Article 52(4) and (5) of the
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European Patent Board introduced the concept of a purpose-limited-
substance claim to extend protection for new discoveries of known
substances.7° In 1984, the European Patent Board in EISAI reiterated
that claims directed to the use of a known substance or composition for
the manufacture of a pharmaceutical preparation for a specified new and
inventive therapeutic application will be eligible for European patent
protection.7' Thus in Europe, the first use (usually medical) of a known
product (protected by a product patent) is patentable by the use of a
purpose-limited-product claim. The second and further use of the same
substance can be patented provided the claims are directed to the use of
the substance or composition for the manufacture of the specific
inventive application (usually therapeutic).72  The required novelty for
such pharmaceutical substances is derived from the new use, irrespective
of whether there was a previously known pharmaceutical or other use for
the same substance.73 The claim format, known as "Swiss claims," falls
outside the exclusion under Article 52(4) of the European Patent
Convention.74 The role of Swiss claims is merely to protect the new use
of the known compound or composition.7" Thus in Europe, a third party
inventing a new use of a patented or known product can get patent
protection limited to marketing the product for the new use. By
extension, a third party inventing a new process of producing a patented
product can, subject to disclosing a new use, get limited patent protection
for the product.
7
3. Comparison with Developing Nations.
The current patent regimes of developing nations77 protect novel
processes of producing known products (in inventions relating to food,
EPC). Article 52(4) of the European Patent Convention states that:
[m]ethods for treatment of the human or animal body by surgery or therapy and diagnostic
methods [practiced] on the human or animal body shall not be regarded as inventions which are
susceptible of industrial application within the meaning of paragraph 1. This provision shall not
apply to products, in particular substances or compositions, for use in any of these methods.
European Patent Convention, Oct. 5, 1973, art. 52(4), http://www.european-patent-
office.org/legal/epc/e/mal.html#CVN. Article 54'of the European Patent Convention discusses
novelty and preserves the patentability of any substance or composition, comprised in the state of the
art, provided its "use" is not comprised in the state of the art. Id. at art. 54.
70. See Hoffman-La-Roche/Pyrrolidine Derivatives, [1984] E.P.O.R. at 595-96.
71. EISAI/Second Medical Indication, Case G 05/83, [1984] E.P.O.R. 241, 246 (EPO Enlarged
Bd. App.).
72. Id. The court clarified that a European patent with claims directed to the use may not be
granted for the "use of a substance or composition for the treatment of the human or animal body [as]
therapy." Id. 18.
73. Id. [ 14-20.
74. Id. See generally Pharm. Mgmt. Agency Ltd. v. Comm'r of Patents [2000] 2 N.Z.L.R. 529.
75. EISAl/Second Medical Indication, [1984] E.P.O.R. 20.
76. See EPO GUIDELINES, supra note 65, at pt. C, ch. III, para. 4.7b.
77. See supra note 5 (providing definition of "current patent regime").
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medicine, and chemicals) although the product is not patent-protected.7 s
The difference is that under the process patent regimes of developing
nations, different patents will protect each of the processes of producing
one product. The product patent regime of developed nations
presumably protects first generation product, while such protection is not
available in the process patent regime. However, the interpretation of
claims adapted, for instance in Atlantic, has resulted in protecting the
innovative processes to the limited exclusion (or protection) of the
product. In essence, the Atlantic judgment creates the same end result
that would be derived from a process patent regime in developing
nations.79 Both the process patent regime used in developing nations and
the use of special claiming techniques within a product patent regime
used in the developed nations create the same effect of facilitating the
duplication of a known product using an innovative process. Thus, the
systems in developed nations indirectly tend to facilitate the same results
that are obtainable in developing nations which encourage novel
methods of producing known products.
Hypothetically, assume that A Corp is the patent owner for a
pharmaceutical product MNO claimed using a product-by-process claim,
where MNO is manufactured using the formula X + Y + Z. If B Corp
manufactures MNO using XY + Y + ZC, under the controlling Atlantic
ruling, B Corp does not infringe the patent on MNO. Therefore, B Corp
will be able to manufacture and effectively market MNO. In Europe, B
Corp can obtain a patent on MNO using the purpose-limited-product
claim subject to claiming a new use for MNO. However, if A Corp
applied for patent protection in a developing country like India, under
the process patent regime (which developed nations oppose), A Corp
would get process protection for X + Y + Z only and not for the product
78. See, e.g., Indian Patents Act, supra note 9, § 5 (stating that "no patent shall be granted in
respect of claims for the substances themselves, but claims for the methods or processes of
manufacture shall be patentable"). For example, in the case of chemical processes, substances that are
intended to be used as or capable of being used as food or medicine can garner patent protection for
the process, but not the substance. But cf Ad. Thermoplastics Co. v. Faytex Corp., 974 F.2d 1279,
1280-81 (Fed. Cir. 1992) (Rich, J., dissenting) (relating to a chemical process).
79. Judge Rich, dissenting from the Federal Circuit's refusal to examine Atlantic Thermoplastics
en banc, traces the similarity between the effect of the Atlantic panel and the patent regimes of
developing nations. At. Thermoplastics Co., 974 F.2d at 1280-81. He quotes Roger A. Brooks,
assistant vice president of the Pharmaceutical Manufacturers Association, and adds that:
more than 100 research-based members of PMA are highly dependent on intellectual property
protection to provide the incentive to invest risk capital. Mr. Brooks stated: "In the
pharmaceutical industry, innovation comes at a premium cost. And R&D productivity is
measured generally in terms of an individual's or nation's ability to develop what we call new
chemical entities, or NCEs. The cost of developing an NCE continues to rise each year. For
example in 1976, the cost of moving an NCE from laboratory to market was $54 million. By 1990,
this figure has risen nearly fivefold to over $230 million per NCE." He then pointed out that only
one out of 5,000 or 10,000 compounds discovered ever make it to the market.
Id. Judge Rich also adds that, "[t]his kind of innovative R&D is not going to be encouraged by the
rule just laid down by the Atlantic panel." Id. Thus, Judge Rich specifically identifies that the
pharmaceutical industry would be affected if competitors are able to make the same product using a
different process. Id, Incidentally, this is what third world countries allow and even encourage their
pharmaceutical manufacturers to indulge in.
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MNO. B Corp can get a process patent for X + Y + ZC and market
MNO as well. Ultimately, the bottom line is that in both developed and
developing nations, B Corp can manufacture and market MNO subject
to not using X + Y + Z. Thus, interestingly, the result is the same for B
Corp in both the United States and India.
In analyzing the Atlantic decision, scholars have observed that:
[a] complex biological or chemical claim would be limited to the
exact process by which the claimant described it, permitting other
inventors to develop new, and possibly more economical, processes
for making the same product. The limitation provides greater
incentive to create more efficient processes because the discoverer
of the new process can profit from both the process and the end
product.s°
Developing a more economic process of producing a patented
product is exactly what the third world generic drug industries already
do. Viewed in light of the Atlantic decision, some of the generic drugs
from developing nations, currently termed "copycat" drugs, may actually
be valid process innovations since they use a. different process for
producing the patented products. Whether a particular generic drug
actually amounts to a patentable innovation can only be resolved on a
case-by-case basis depending on the extent of the improvement's
contribution to the existing material." Developed nations also use other
patent doctrines, like the reverse doctrine of equivalents, to protect
improvements over existing patents.' In effect, developed nations oppose
that which they themselves practice. 82
4. Malady After Developing Nations Become TRIPS Compliant
A malady will arise when the developing nations ultimately move to
a product patent regime in 2005 as required by TRIPS. Under a product
patent regime, devoid of the use of appropriate claims, innovative
processes or uses of known products may be left unprotected. Once
developing nations embrace the TRIPS patent regime, unless they
incorporate the claiming nuances, process innovations may become
unprotected. That is, TRIPS requires developing countries to award only
product patents. In effect, novel processes, not necessarily excluded
from protection under TRIPS, may become unpatentable in developing
countries because of a lack of sufficient claiming or even interpretative
techniques. Consequently, inventions patentable in developed nations,
80. Passler, supra note 39, at 252.
81. See Mark A. Lemley, The Economics of Improvement in Intellectual Property Law, 75 TEX.
L. REv. 989, 1008 (1997) (discussing how U.S. patent law provides for patenting of improvements, and
what improvements qualify for patent protection).
82. Id. at 1013 (discussing that patent law has more protection for improvements than copyright
law). See generally Ragavan, supra note 6, at 154-55.
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using sophisticated procedural mechanisms or patent doctrines, will fall
outside the TRIPS-compliant patent legislation of developing nations.
Developing countries complying with TRIPS will amend the patent
legislation and incorporate a product patent regime without actually
strengthening the procedural sophistication." Under the post-TRIPS
regime, in a developing nation like India, A Corp (in the hypothetical
above) will become eligible for a product patent over MNO. Since
claiming techniques will not be adequately developed, A Corp will use
the general guidelines for claiming in India (as detailed in Section II).
The patenting of MNO by A Corp will vest the complete monopoly over
MNO in A Corp during the patent term. B Corp's novel process for
producing MNO, being X + Y + ZC, will infringe A Corp's patent in
MNO owing to a product patent regime lacking in procedural
sophistication. Thus, A Corp's patent will block further innovations over
MNO. The resulting malady is that B Corp's process of making MNO,
although not considered infringing in the United States, will be
considered infringing in India. Therefore, India (and other similarly
placed developing nations) will be deprived of the benefits of process
innovations like that of B Corp. It is also possible that the innovative
process of B Corp will either fall into the public domain or will be
patented in a developed nation depending on the patent sophistication of
B Corp. Several developing nations, like India, Brazil, and Thailand,
house generic drug industries specializing in process innovation. 4 After
these nations implement the TRIPS-compliant patent legislation, the
process innovations in the developed nations may be left unprotected.
The Hoechst Corporation case" demonstrates the above
proposition. Hoechst owned Indian patent no. 58716 for the
"[m]anufacture of New Sulphonyl-Ureas, Salts of those Compounds and
of Anti-diabetic Preparations containing such Compounds." 86  The
specification detailed that the invention was comprised of sulphonyl
ureas.' Claim 11 related to the "process as claimed in claim 1 wherein
thioureas were treated with agents eliminating the sulphur."88 The very
broad claim 22 referred to the "compounds of the formula... [and] the
drawings, whenever obtained according to claims 1-15. "89 One such
compound was tolbutamide.
83. It will take the developing nations a long time to understand the nuances of the
implementation procedures. In the interim, the product patent regime will function with rudimentary
claim and specification requirements.
84. See, e.g., Ragavan, supra note 6, at 173.
85. Farbwerke Hoechst & Bruning Corp. v. Unichem Lab., 1969 A.I.R. 56 (Bom.) 255.
86. Id. at 263.
87. Id. The sulponyl ureas represented the general formula R-S02-NH-CO-NHR.1 in which R
represented a phenyl radical with certain limitations in regard to the number of carbon atoms, and R.1
represented a hydrocarbon radical with certain limitations in regard to the number of carbon atoms as
well. Id. at 264.
88. Id. at 264.
89. Id. at 263.
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The Haffkine Institute, a public sector firm, produced tolbutamide
from locally available raw materials and patented the process.90
Tolbutamide was used to prepare a drug to reduce blood sugar.9 The
patent for a new process of preparing tolbutamide was licensed to
Unichem Labs, a domestic drug producer.9 Hoechst filed a suit claiming
that the Haffkine patent for tolbutamide lacked novelty since
tolbutamide was a by-product of Hoechst's 58716 patent.93
The Bombay High Court verified that the compound tolbutamide
was derived from carbutamide, a compound developed in 1955 with
hypoglycaemic properties. Carbutamide, however, was withdrawn from
the market by 1957 as being unsuitable for prolonged administration.94
Hoechst's employee, Dr. Aumuller, removed the amino group in
carbutamide and added a methyl group, thereby inventing tolbutamide,
which eliminated the defects of carbutamide but preserved the
hypoglycaemic properties.9 Haffkine Institute, however, produced
tolbutamide by desulphurizing benezene sulphonyl thioureas with
hydrogen peroxide.96 The processes followed by Haffkine and Hoechst
to produce tolbutamide were totally different. In spite of the different
processes, however, the Bombay High Court found in favor of Hoechst.97
Haffkine's process of producing tolbutamide was held to infringe
Hoechst's patent only because India, at that time, lacked procedural
mechanisms to either limit Hoechst's protection or merely protect
innovative processes of making known products.
Notably, the Hoechst case was decided in 1969 under the erstwhile
Indian Patents and Designs Act of 1911, which embodied a product
patent regime.98 Once the product patent regime required by TRIPS is
established, the operation of the patent regime will be similar to that of
the 1911 patent law unless procedural mechanisms are established for
protecting innovative processes. Interestingly, had Hoechst applied for a
patent in the United States using the product-by-process claim to seek a
patent, Haffkine's process would be considered non-infringing. Even if
Hoechst did not use product-by-process claims, Haffkine's process could
be considered non-infringing under 35 U.S.C. § 271(g), which provides
that a "product which is made by a patented process will, for the
purposes of this title, not be considered to be so made after-(1) it is
materially changed by subsequent processes; or 2) it becomes a trivial
and nonessential component of another product."




94. Id. at 268--69.
95. Id.
96. Id. at 258.
97. Id. at 273.
98. Indian Patents & Designs Act, 1911 (1929).
99. 35 U.S.C. § 271(g) (1994).
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Unfortunately, developing countries lack the understanding of the
complexities of the claiming mechanisms. They are unable to articulate a
definitive form of protection or use the existing mechanisms to tailor an
effective protection for their knowledge sources. For example, Swiss
claims, available in Europe, can be used effectively to protect knowledge
of medicinal uses derived from traditional knowledge sources of the
indigenous people by construing the knowledge as analogous to either
first or second medicinal use. An appropriately modified purpose-
limited-product claim may be used to limit the scope of the protection to
the use of indigenous material and enable the manufacture of
medicaments for specified therapeutic applications. Complying with
TRIPS could only increase the handicap. For example, while developed
nations would facilitate protection of process innovations over known
products, developing nations could be denied the luxury post-TRIPS due
to the rudimentary patent procedures."3°
Intellectual property harmonization would enable developed
nations to appropriate and protect information left unprotected in
developing nations simply by using superior procedural techniques.
Considering that developing nations have a niche in process innovations,
research and development can be stunted by imposing a product-
patenting regime without introducing adequate procedural mechanisms.
Thus, the TRIPS patent policy by itself has the potential to result in
increased inequality of intellectual property protection.
B. Claim Limitations & Protection of Minor Innovations
Procedural mechanisms, especially claims, enable the patent systems
of developed nations to be more sophisticated by creating the flexibility
to protect a wider range of inventions within the same product
classification. Consequently, inventive activity is encouraged, resulting
in inventions which are distinguished through functional or structural
additions on existing products.'' For example, in Dolly Inc. v. Spalding
& Evenflo Cos.,"°2 the patented device related to a portable and
adjustable child's play chair with a stable rigid frame with a seat and back
panel."3 The claimed invention related to a portable and adjustable
child's play chair, but it did not include a stable rigid frame in the claim
language. Instead, the seat and back panel of the device fit together to
form a rigid frame upon assembly. m The court applied the doctrine of
equivalents to hold that a stable rigid frame assembled from the seat and
100. But see EPO GUIDELINES, supra note 65, at pt. C, ch. III, para. 4.7b (stating that a product is
not rendered novel merely because it is produced by means of a new process).
101. See generally Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605 (1950); Warner-
Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17 (1997) (discussing the doctrine of equivalents).
102. 16 F.3d 394 (Fed. Cir. 1994).
103. Id. at 396.
104. Id. at 397.
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back panels was not the equivalent of a separate stable rigid frame set
out in the claim language. Thus the second child's play chair, which
was a replica of the patented invention except for the singular feature of
a rigid frame, was held to not infringe the patent. In effect, precise
claiming furthers innovation by recognizing two similar products
performing the same functions differentiated by merely one claim
limitation (or sometimes more).
Similarly, in In re Donaldson Co.," 6 the patent related to "industrial
air-filtering devices often referred to as 'dust collectors. ,,10 7 Claim 1 was
an apparatus claim reciting an "air filter assembly for filtering air laden
with particulate matter, said assembly comprising [a plurality of
elements].' 8 On appeal, the patentee conceded that a single prior art
reference (Swift) met every limitation in claim 1 except for the limitation
of a "means, responsive to pressure increases in said chamber caused by
said cleaning means, for moving particulate matter in a downward
direction."' ' The Board held that the last limitation was also met by the
prior art because Swift disclosed the recited function."0 On appeal the
Federal Circuit considered the issue en banc and unanimously reversed
the Board's decision. 1' The Federal Circuit held that if the prior art does
not disclose the same structure, or an equivalent structure, the claim
element is not literally met and the claim is not anticipated under § 102.1
If the prior art does not render the claimed structure or its equivalent
obvious, the claim is not obvious under § 103."' In essence, two dust
collectors that differed by only a single element were both patented.
Thus, separate patents can protect products performing the same
function and manufactured by the same or similar processes by the use of
appropriate claims.
A system that has a product patent regime without complementary
procedural foundations (like the one contemplated for the developing
countries under the WTO) will effectively block the patenting of
products within the same range. In the above examples, the patenting of
one air-filtering device will effectively stop any other air filters from
being patented. Similarly, the patenting of one child play chair may
prevent improved chairs, even if safer, from being patented. Such a
result can erode the incentive for further research and development. A
product patent regime cannot be blindly thrust upon a nation unless
there is an adequate understanding of the nuances of working that policy
effectively by using the appropriate tools.
105. Id. at 400.
106. 16 F.3d 1189 (Fed. Cir. 1994).
107. Id. at 1190.
108. Id. at 1191 (internal references omitted).
109. Id. at 1192.
110. Id.
111. Id. at 1197.
112. Id.




The following section examines efforts in the United States to
promote the biotechnology ("biotech") industry by using patent policies
to demonstrate that patent procedures and doctrines create flexibilities
within the product patent regime, thus facilitating industrial growth. The
development of biotech patenting in the United States exemplifies the
effective use of patent mechanisms to further industrial development.
The patenting techniques adopted by the United States have furthered
industrial development by fostering biotech patenting and then following
it with a strong patent regime that sustains industrial development.
Understanding the working of these procedural mechanisms may help
developing countries in their post-TRIPS legislative attempts to draft
patent policies.
114
In 1980, Diamond v. Chakrabarty"' paved the way for the
development of biotech industries by holding microorganisms patentable
under 35 U.S.C. § 101.116 The protection offered in Chakrabarty enabled
the establishment of the biotech industry. 1 7  The invention in
Chakrabarty was an oil-eating "bacterium from the genus Pseudomonas
containing therein at least two stable energy-generating plasmids, each of
said plasmids providing a separate hydrocarbon degradative pathway."" 8
Chakrabarty transferred camphor and octane degrading plasmids into a
single Pseudomonas bacterium. 19 The invention was meant to increase
the efficiency of controlling oil spills.
Chakrabarty's patent application claimed (1) the process of
producing the bacteria, (2) the inoculums of carrier material (e.g., straw
to float on water with the bacteria) along with the plasmid-injected
Pseudomonas, and (3) the Pseudomonas itself.120 The examiner allowed
all the claims except for the claim on the bacteria, reasoning that
microorganisms are products of nature and living things are not
patentable subject matter under the Patent Act of 1952.121
The Supreme Court granted certiorari to hear the issue relating to
the patentability of living matter.'22 The Court succinctly determined
that the relevant distinction for determining patentability was not
between living and inanimate things, but between products of nature,
114. See TRIPS, supra note 2, at art. 27, para. 3.
115. 447 U.S. 303 (1980).
116. Id. at 309; 35 U.S.C. § 101 (2000) ("Whoever invents or discovers any new and useful process,
machine, manufacture, or composition of matter, or any new and useful improvement thereof, may
obtain a patent therefor, subject to the conditions and requirements of this title.").
117. BIOTECHNOLOGY INDUSTRY ORGANIZATION, IMPORTANCE OF INTELLECTUAL PROPERTY,
(2004), at http://www.bio.org/ip (last visited Nov. 10, 2004).
118. Chakrabarty, 447 U.S. at 305.
119. Id. at305n.1.
120. Id. at 305-06.
121. Id. at 306.
122. Id. at 305.
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whether living or not, and human-made inventions.123 The Court
highlighted that although the original Pseudomonas was a product of
nature, the introduction of a new genetic material capable of degrading
oil into the bacterium constituted an invention. 24  Thus, the Court
posited the landmark proposition that all human creations resulting from
genetic engineering, whether living or inanimate, were eligible for patent
protection. 
25
The mere availability of a clear policy providing patent protection
for genetic engineering encouraged research and development.1 26 The
possibility of patent protection on genetic material created tremendous
financial potential for biotech companies and encouraged biotech
investments.2 7 Thus, Chakrabarty marked the beginning of biotech
advances. The biotech industry, particularly in the United States, was
poised for cataclysmic changes after Chakrabarty.
By 1991, the Federal Circuit, through Amgen v. Chugai, 8 lowered
the threshold for biotech patents, thereby encouraging the U.S. biotech
industry to file more patent applications. 129 Amgen involved issues of
patent validity and infringement with respect to two inventions involving
erthropoietin.13 U.S. Patent 4,703,008, owned by Amgen Inc., was
entitled "DNA Sequences Encoding Erthropoietin," and it claimed
"purified and isolated DNA sequences... encoding erythropoietin [and]
host cells transformed or transfected with a DNA sequence.",
31
Genetics Institute, Inc. ("GI") held a product patent for
erythropoietin compositions. Amgen accused GI and its partner
Chugai of infringing Amgen's patent.133 Amgen alleged that producing
recombinant erythropoietin by transforming mammalian host cells
containing vectors with DNA coding for creating human erythropoietin
infringed its patent. 34  GI and Chugai counterclaimed that Amgen's
patent was invalid under 35 U.S.C §§ 101, 102, 103, and 112.35 The issue
under § 102(g)'36 arose since the defendants alleged that their employee,
Fritsch, was the first to conceive the invention in 1981 and was diligent
until reducing the invention to practice in May 1984.37 GI argued that
123. Id. at 303.
124. Id. at 305, 313.
125. Id. at 305; see id. at 318 (Brennan, White, Marshall, and Powell, JJ., dissenting).
126. See Geri J. Yonover, What Hath (Not) Chakrabarty Wrought: From the Mouse That Roared
to Hello Dolly and Beyond, 32 VAL. U. L. REV. 349,358 (1998).
127. See id.
128. 927 F.2d 1200 (Fed. Cir. 1991).
129. See generally id. at 1205-06.
130. Id. at 1203-04.
131. Id.
132. Id. at 1203.
133. Id. at 1204.
134. Id.
135. ld. at 1204-05.
136. 35 U.S.C. § 102(g) (1988).
137. Amgen, 927 F.2d at 1205-06.
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Fritsch should be held as the prior inventor under § 102(g) over Lin,
Amgen's employee, who reduced the invention to practice in 1983.138
The court held that the conception of a chemical compound
necessitates that the inventor have "a mental picture of the structure of
the chemical, or is able to define it by its method of preparation, its
physical or chemical properties, or whatever characteristics sufficiently
distinguish it."'' This idea was enunciated as the doctrine of
simultaneous conception and reduction to practice."4  Essentially, an
invention reasonably conceived in the inventor's mind was capable of
fulfilling the patentability requirements. Additionally, the court did
not seek disclosure of the actual DNA sequence, but only that the DNA
be "defined" in a manner distinguishing it from other chemicals, along
with a description of how to obtain it. 42 Amgen enabled patentability of
an adequately described DNA although the inventor may be both
unaware of its structure and nowhere near disclosing the actual
structure. 143 The Federal Circuit's timely move in Amgen made biotech
patents easier to obtain, thereby encouraging biotech research. All that
was required for scientists to obtain patents was to adequately conceive
the DNA sequence and appropriately describe the DNA, distinguishing
it from the prior art with details on how to obtain it.
Standards for biotech patenting were further lowered in In re
Deuel'" by minimizing the nonobviousness requirement.' The Deuel
court favored the applicants by reducing the obviousness standards from
Amgen and redefining the legal test of prima facie obviousness.' 6 The
invention in Deuel related to isolated and purified DNA and cDNA




140. Id. at 1206-07. The court held that conception is the "formation in the mind of the inventor,
of a definite and permanent idea of the complete and operative invention, as it is hereafter to be
applied in practice." Id. The doctrine of simultaneous conception and reduction to practice evolved
to determine priority of invention. An inventor may be unable to establish conception until the
invention has been reduced to practice through experimentation. Id
141. Id. at 1209.
142. Id. at 1206.
143. Id. (requiring merely that the DNA sequence be disclosed in a manner that sufficiently
distinguishes it; the DNA sequence could be defined by its actual structure as well as its method of
preparation).
144. 51 F.3d 1552 (Fed. Cir. 1995).
145. Id. at 1559-60. Deuel isolated and purified HBGF from bovine uterine tissue, and
determined the first twenty-five amino acids of the N-terminal sequence. Deuel then isolated cDNA
encoding for the bovine HBGF by screening the bovine DNA library with an oligonucleotide probe.
Deuel purified the cDNA and found that its sequence consisted of 1196 nucleotide base pairs. The
bovine cDNA was then used as a probe to isolate and purify human placental HBGF. Deuel isolated,
purified, and then determined the sequence of the human placental cDNA which consisted of 961
nucleotide base pairs. With this knowledge, Deuel predicted the complete amino acid sequence of the
human placental HBGF. Id. at 1555.
146. Id. at 1557-60; see also In re Bell, 991 F.2d 781, 784-85 (Fed. Cir. 1993).
147. Deuel, 51 F.3d at 1555. The court also stated that the claims on appeal were independent.
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HBGFs stimulate mitogenic activity and facilitate repair of damaged
tissue. The patent examiner cited a combined teaching of the Bohlen
and Maniatis prior art references to reject Deuel's application as prima
facie obvious under § 103.1'9 The court considered "whether the
combination of a prior art reference teaching a method of gene cloning,
together with a reference disclosing a partial amino acid sequence of a
protein, may render DNA and cDNA molecules encoding the protein
prima facie obvious under § 103. "15 Structural claims were used in the
patent application."' The court agreed that structural similarity between
the compounds in the prior art and the claims may provide a basis for an
obviousness rejection by establishing a motivation to make the claimed
compound . The court added, however, that although a general method
of isolating DNA molecules is known, a specific DNA molecule isolated
is prima facie nonobvious and patentable. 53 Thus, the court rendered
genes isolated from well-known and obvious methods as "nonobvious"
and thereby patentable.
The Amgen decision rendered an adequately conceived DNA
patentable. The Deuel decision made obviousness rejections for biotech
patents scarcer. 114 Deuel also enabled patenting of miniscule inventions
by lowering the obviousness bar.' Economically, the lowering of the
obviousness standard boosted the biotech companies."5
On the one hand, based on prior art knowledge, the
biotechnologists know that sequencing around twenty amino acids is
sufficient to obtain the cDNA sequence that codes for a particular
protein, absent unforeseen difficulties. On the other hand, under current
law, the expected product of this scientifically obvious manipulation is
legally unobvious and thus patentable. 57
The lowering of the non-obviousness requirement reduced the
minimum threshold that social value inventions were required to
contribute to make it worth the trouble of issuing and enforcing a patent.
It resulted in biotech companies patenting minor inventions and over-
claiming all innovations." The benefit was that it led to several
148. Id. at 1554.
149. Id. at 1555-56.
150. Id. at 1557.
151. Id.
152. Id.
153. Id. at 1559 ("The existence of a general method of isolating cDNA or DNA molecules is
essentially irrelevant to the question whether the specific molecules themselves would have been
obvious, in the absence of other prior art that suggests the claimed DNAs.").
154. Shraddha A. Upadhyaya, The Postmodern Written Description Requirement: An Analysis of
the Application of the Heightened Written Description Requirement to Original Claims, 4 MINN.
INTELL. PROP. REV. 65,107-09 (2002).
155. Id. at 107-0&
156. See id. at 109; Sara Dastgheib-Vinarov, A Higher Nonobviousness Standard for Gene Patents:
Protecting Biomedical Research from the Big Chill, 4 MARQ. INTELL. PROP. L. REV. 143,178 (2000).
157. Anita Varma & David Abraham, DNA Is Different: Legal Obviousness and the Balance
Between Biotech Inventors and the Market, 9 HARV. J.L. & TECH. 53,78 (1996).
158. See Dastgheib-Vinarov, supra note 156, at 143.
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innovations and inventions in biotech and pharmaceuticals. Deuel
greatly facilitated the United States' growth in biotech patent
applications and allowed it to prosper from a rapidly growing biotech
industry. 9  Deuel together with Chakrabarty enhanced the proliferation
of intellectual property rights in biomedical research. However, the
disadvantage was the underutilization of the resources because too many
patent owners blocked each other.' 6 The biotech industry was faced with
a "spiral of overlapping patent claims in the hands of different owners.'161
These realities mandated that the free-for-all biotech patent applications
be capped.62. The cap came in the form of the heightened written
description requirement in Regents of the University of California v. Eli
Lilly & Co. 163  In an effort to limit the overly broad biotech patents
created by Deuel, the Federal Circuit decided in Eli Lilly to heighten the
written description requirement.' 6 Thus, the Federal Circuit made a
deliberate and conscious effort to slow the race for biotech patents that
had been made easier by previous decisions. In the 1990 case, the
University of California brought a suit against Eli Lilly alleging
infringement of two patents relating to recombinant DNA technology.' 
6
Specifically, the patents related to recombinant plasmids and
microorganisms that produce human insulin.167 The '525 patent, issued
from a 1977 application, related to proinsulin and preproinsulin cDNA
sequences in rats. 68  The '740 patent, issued from a 1979 patent
application, related to the "cDNA sequences 69 and the development of
'tailoring' techniques for the incorporation of the human [proinsulin]
cDNA into a recombinant plasmid.' ' 70  The district court ruled that
claims 1, 2, and 4-7 in the '525 patent were invalid under §112, 1,
159. Upadhyaya, supra note 154, at 109 ("The Chakrabarty and Deuel decisions... spur[red]
biotechnology innovation and progress.").
160. See Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The Anti-
Commons in Biomedical Research, ScI. MAG., May 1, 1998, at 698, available at
http://www.sciencemag.org/cgi/contentlabstract/280/5364/698.
161. Id.
162. Id. at 698-99; see also Dastgheib-Vinarov, supra note 156, at 165, which states:
[B]etween 1990 and 1998, the total number of [biotechnology] patents granted to U.S.
corporations has quadrupled. In contrast, between 1990 and 1998, the total number of patents
issued increased by about sixty percent. This large disparity is cause for concern. It suggests that
the biotechnology industry is using the relaxed nonobviousness standard to obtain genomic
patents simply for corporate gain.
163. 119 F.3d 1559 (Fed. Cir. 1997); see Upadhyaya, supra note 154, at 109.
164. Eli Lilly, 119 F.3d at 1567.
165. Id. at 1566-69.
166. Id. at 1562.
167. Id. A person unable to produce insulin suffers from diabetes. Prior to recombinant
technology for producing human insulin to treat diabetes, animal insulin was used, which caused
allergic reactions. Id.
168. Id.
169. The patent covered human proinsulin and preproinsulin. Id. at 1563.
170. Id. Eli Lilly produced human proinsulin by using "semi-synthetic DNA to yield a cleavable
fusion protein." Id. The produced fusion protein "consists of a bacterial protein, a 'cleavable linkage'
consisting of a single methionine residue and human [proinsulin]." Id. The human proinsulin was
obtained by cleaving it from the fusion protein. Id.
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because the specification did not provide an adequate written description
of the cDNA covered in the claims.' The Federal Circuit affirmed,
basing its holding upon lack of written description.
The Federal Circuit held that for claims relating to genetic material,
"a generic statement such as 'vertebrate insulin cDNA' or 'mammalian
insulin cDNA,' ... is not an adequate written description of the genus."'' 3
Such a written description "does not distinguish the claimed genus from
others, except by function.', 7 4 The Federal Circuit required that genes be
specifically defined along with distinguishing structural features of the
genus.' It was here that the court articulated the "precise definition"
test."' The Federal Circuit held that a specification should have an
adequate written description of a DNA molecule with "'a precise
definition, such as by structure, formula, chemical name, or physical
properties,' not a mere wish or plan for obtaining the claimed chemical
invention.', 7 7  Finally, the Federal Circuit held that "[w]ithout the
heightened specificity requirement, a genus defined entirely by function
fails to establish an adequate written description of the specification. ,17
Earlier the Federal Circuit in Fiers v. Revel179 had "created an
exception to the rule that a claim included in the application cannot be
rejected for lack of description. '""' The Fiers court emphasized on
specificity by holding that "[w]hile one does not need to have carried out
one's invention before filing a patent application, one does need to be
able to describe that invention with particularity."1' Thus, the court in
Eli Lilly used the Fiers rule effectively.
The U.S. patent policy on biotech patenting since the 1980s has been
uniformly stringent. The intervention by the Federal Circuit in fine-
tuning application requirements, in effect, diluted the stringency of the
policy and facilitated investments. When biotech investments increased,
the United States raised the application standards to streamline biotech
patents. Procedural requirements were used to induct the required
flexibility into the seemingly stringent patent policy to achieve the
required industrial growth. Without amending the policy, the patenting
bar that was reduced in Deuel was increased in Eli Lilly using the written
description requirement. In summary, Chakrabarty facilitated the
establishment of biotech industry; Deuel promoted proprietary rights
171. Id. at 1566.
172. Id. at 1562.
173. Id. at 1568.
174. Karczewski, supra note 17, at 1078 (quoting Eli Lilly, 119 F.3d at 1568).
175. Eli Lilly, 119 F.3d at 1566-67 (quoting Fiers v. Revel, 984 F.2d 1164, 1171 (Fed. Cir. 1993))
("A definition by function.., does not suffice to define the genus because it is only an indication of
what the gene does, rather than what it is."); see also Karczewski, supra note 17, at 1078-79.
176. Eli Lilly, 119 F.3d at 1566.
177. Id. at 1566-67 (quoting Fiers, 984 F.2d at 1171).
178. Id.; see also Karczewski, supra note 17, at 1078.
179. 984 F.2d 1164 (Fed. Cir. 1993).
180. ADELMAN, supra note 8, at 611.
181. Fiers, 984 F.2d at 1169.
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that benefited the biotech industry; and Eli Lilly streamlined the industry
by ultimately regulating the free-for-all biotech patents.
Therein lays the model for developing countries for inducing clarity
and vision that will focus policies on national needs. TRIPS advocates
the application of a harmonized patent policy for developing countries.
These countries are at the crossroads of development and need flexibility
in sectors with industrial growth. Since developing countries are new to
the workings of patent policies, they are unaware of the various modes of
creating flexibility within systems. Much to their disadvantage,
developing countries are more likely to use the TRIPS patent policy
without fully exploiting the opportunities to use such flexibility.
Developing countries need to understand that amendments made in
compliance with international treatises should incorporate appropriate
standards and procedures to retain the national focus of the policies.
V. CONCLUSION
If developing nations lack the procedural pillars to support the
structure of patent policies, certain inventions and innovations will be
denied patent protection. Thus, harmonizing patent systems without the
supporting procedural backup will not create the economic incentive for
which developing nations embraced TRIPS. Domestic industries will be
encouraged to invest when local inventions become protected. In turn,
third world governments will be provided with an incentive to take a
stronger stance against intellectual property infringements. 18
Developing nations, if unable to effectively protect local innovations,
may reduce research and development initiatives. Demanding
recognition for the intellectual property of the developed nations without
educating developing nations on corresponding mechanisms to protect
local innovations will weaken government willingness to enforce
intellectual property laws strictly. The government's willingness to
enforce is one of the key factors for intellectual property harmonization
since conscious government involvement is required to reject the• 13
industrial bases offered by counterfeit markets. The solution for
intellectual property harmonization lies in adequately equipping
developing nations with appropriate tools to promote growth by
encouraging local invention. Unfortunately, patent harmonization will
182. See generally In Praise of the Real Thing, THE ECONOMIST, May 17, 2003, at 12.
183. Id. The strongest proponents of intellectual property rights, Europe and the United States,
built their industrial base a century ago by copying others. Id. See also Ruth Gana Okediji, Copyright
and Public Welfare in Global Perspective, 7 IND. J. GLOBAL LEGAL STUD. 117, 123,136 (1999).
184. There are several examples to prove that industrialization improves intellectual property
protection. The embracing of copyright laws by the Indian computer industry is a case in point. Once
the Indian computer industry realized its global competence, it canvassed the government for
intellectual property legislation. See A.K. CHAKRAVARTI, Protecting Proprietary and Security Rights
in Cyberspace: Initiatives in India, at http:/lwww.unesco.org/webworldlinfoethics-2/englpapers/
paper_15.htm (last visited Nov. 10, 2004). The computer industry in India aided the government in
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ultimately suffer unless developing countries can benefit from it.
Otherwise, even developing countries that amend patent legislation to
become TRIPS compliant will relax implementation.
amending the copyright legislation to suit industrial needs. Id. See also Imitating Property Is Theft,
THE ECONOMIST, May 17, 2003, at 54 (noting that until Japan became industrialized, it was the hot
spot for counterfeit products in the 1960s, followed by Hong Kong in the 1970s, and Taiwan and South
Korea in the 1980s; significantly, industrialization had a direct correlation with these countries
clamping down on intellectual property infringement).
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